Eagle Pharmaceuticals - Q1 2023

Executive Summary

• Q1 2023 revenue was $66.305M and diluted EPS was $0.44; adjusted diluted EPS was $1.26 and adjusted EBITDA was $22.325M, while gross margin was 74%.
• Year-over-year comparisons reflect a tough lap versus launch quarter dynamics and the decision to exit vasopressin: vasopressin sales fell to $3.5M from $34.3M in Q1 2022; royalty revenue also declined YoY to $20.084M from $25.786M.
• PEMFEXY net sales reached $22.9M; management estimates commercial (non‑340B) pemetrexed share grew from 6% exiting Q4 2022 to ~15% Q2-to-date, supporting full-year expectations that PEMFEXY sales will exceed 2022 levels.
• The company reaffirmed full-year 2023 guidance (adjusted EBITDA $74–$80M; adjusted non-GAAP EPS $4.20–$4.53; non-GAAP R&D $41–$45M; non-GAAP SG&A $86–$90M) and highlighted a potential accretive acquisition effort; CMS granted a unique J‑code for Byfavo effective July 1, 2023, potentially improving reimbursement and access.
• Stock reaction catalysts: accelerating PEMFEXY share; bendamustine franchise resilience and extended exclusivity (settlements imply potential entry only in Nov 2027 for a key challenger); exit of vasopressin reduces near-term sales but simplifies focus; new Byfavo J‑code should aid hospital adoption; active exploration of accretive M&A in oncology.

What Went Well and What Went Wrong

What Went Well

• PEMFEXY momentum: “Based on internal data and customer feedback, we estimate…our share has now grown to 15% [Q2-to-date],” with Q1 net sales of $22.9M and expectations to surpass 2022 full-year PEMFEXY sales.
• Bendamustine durability: BENDEKA and BELRAPZO combined maintained ~89% U.S. bendamustine share in Q1 2023; management “remain confident in exclusivity into November of ’27,” positioning the franchise as a meaningful contributor for several years.
• Reaffirmed guidance and structural enablers: Company reiterated 2023 guide and secured a unique Byfavo J‑code, with management noting the J‑code “is an important step in facilitating reimbursement and broadening access”.

What Went Wrong

• YoY decline versus launch quarter: Total revenue fell to $66.305M from $115.874M in Q1 2022, driven largely by vasopressin ($3.5M vs $34.3M) and lower PEMFEXY versus launch quarter dynamics ($22.9M vs $37.2M).
• Margin and opex headwinds: Gross margin dipped to 74% (76% in Q1 2022) due to amortization from newly acquired products; R&D rose to $9.3M (from $6.1M) and SG&A to $28.0M (from $22.2M), reflecting pipeline investments and commercial expansion.
• Working capital build and inventory dynamics: Accounts receivable rose to $115.0M as management noted customer inventory levels may be elevated while capturing share in PEMFEXY, adding near-term balance sheet sensitivity.

Transcript

Operator (participant)

Good morning, everyone. My name is Todd, and I'll be your conference Operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals First Quarter 2023 Financial Results. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a Question-and-Answer period. At that time, if you have a question, please press star and one on your telephone keypad. As a reminder, this conference call is being recorded today, May 9th, 2023. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson (Investor Relations Representative)

Thank you, Todd. Welcome to Eagle Pharmaceuticals First Quarter 2023 Earnings Call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle's President and Chief Executive Officer, Scott Tarriff, Chief Financial Officer, Brian Cahill, and Vice President of Medical Affairs, Dr. Mike Greenberg. This morning, Eagle issued a Press Release detailing its Financial Results for the Three Months ended March 31st, 2023. This Press Release and a Webcast of this call can be accessed through the Investor Section of the Eagle website at eagleus.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered Forward-Looking Statements as defined by the Private Securities Litigation Reform Act.

These Forward-Looking Statements are based on information available to Eagle Pharmaceuticals management as of today and involve risks and uncertainties, including those noted in this morning's Press Release and our filings with the SEC. Such Forward-Looking Statements are not guarantees of future performance. Actual results may differ materially from those projected in the Forward-Looking Statements. Eagle Pharmaceuticals specifically disclaims any intent or obligation to update these Forward-Looking Statements except as required by law. A telephone replay will be available shortly after completion of this call. You'll find the dial-in information in today's Press Release. The archive Webcast will be available for 30 days on our website at eagleus.com. For the benefit of those who may be listening to the Replay or archive Webcast, this call was held and recorded on May 9th, 2023.

Eagle may have made announcements related to the topics discussed, so please refer to the company's most recent Press Releases and SEC Filings. We will be discussing Non-GAAP Financial Measures during this conference call in addition to financial information prepared in accordance with US GAAP. These non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with GAAP. A description of these non-GAAP financial measures and reconciliations of these non-GAAP Financial Measures to their most comparable GAAP measures are set forth in our Earnings Press Release available on our website at eagleus.com. I'll turn the call over to Eagle's President and CEO, Scott Tarriff.

Scott Tarriff (President and CEO)

Thank you, Lisa. Good morning, everyone, and thank you for joining our call today. Following on from the outstanding year Eagle had in 2022, we remain well positioned for another strong year in 2023. Our products continue to do well, as you can see from the strong earnings we announced this morning. We expect this momentum to continue and our longer-term growth to come from our pipeline of potential acquisitions. For the First Quarter of 2023, our Net Income was $5.8 million or $0.44 per basic and diluted share, and adjusted Non-GAAP Earnings was $16.5 million or $1.27 per basic and $1.26 per diluted share. Our Adjusted Non-GAAP EBITDA was $22.3 million for the First Quarter. This positions us well to achieve our full year 2023 Guidance, which we reaffirmed.

To be clear, the investments we are making for the future account for much of the expected difference of our earnings in 2023 versus 2022. We are investing to support our products and advance our pipeline, notably CAL02, which bridges much of the year-over-year gap. With the Commercial Infrastructure already in place, we believe we will be able to capture synergies through a potential acquisition target. Let's look at the products. During the First Quarter PEMFEXY Net Product Sales totaled $22.9 million. We believe we are well on our way to surpassing the $67 million recorded for the full year of 2022. As you recall, we exited the fourth quarter of last year with a 6% share of Commercial Non-340B Pemetrexed usage in Community Oncology in the United States.

Based on the internal data and customer feedback, we estimate that as of the second quarter to date, that our share has now grown to 15%. We expect growth to continue throughout the year and believe that the market share at the end of Q2 could be greater than the current 15%. PEMFEXY remains an important asset for us. As you would recall, we eliminated the Royalty on the first $85 million of profit on PEMFEXY beginning October 1, 2022, and a reduced Royalty thereafter. In exchange for a One-Time Payment of $15 million. So far, that is looking like a great decision. Moving on to our Bendamustine Franchise. As we have discussed in the past, our Bendamustine Franchise faced new competition for the first time beginning on December 7, 2022.

Since that time, we continue to be pleased with the strong performance of Bendeka and BELRAPZO in the marketplace. It is our belief that Bendeka is a beneficial product for patients and healthcare providers. Together, Bendeka and BELRAPZO maintained approximately 89% share of the Bendamustine U.S. Market for the First Quarter of 2023, compared to approximately 90% historically. In the First Quarter, we reached the Settlement Agreement with Dr. Reddy's. Eagle has asserted its Orange Book listed patents against Dr. Reddy's related to its New Drug Application referencing Bendeka. The settlement follows our previously announced settlements with Hospira and Accord Healthcare related to their new drug applications referencing Bendeka. Other than one recent challenger, which is for a proposed powder, not liquid formulation, all existing cases have now been settled.

We remain confident in exclusivity into November of 27, which we believe positions Bendamustine to be a significant contributor for several more years. Turning now to the Acacia products, Barhemsys and Byfavo. Combined Net Sales of the two products totaled just shy of $1 million in the First Quarter. Barhemsys and Byfavo product sales are up 32% sequentially versus Q4 of '22. Although this is a small base, it is a very solid showing, and we expect their shares to continue to grow nicely. Just last week, we announced that CMS established a unique product-specific Billing Code for Byfavo, which, as you may recall, is a short-acting sedative for procedures lasting 30 minutes or less. This new J-code is effective on July 1 of '23.

We believe the establishment of a unique J-Code for Byfavo is an important step in facilitating reimbursement and broadening access to this innovative sedation drug. Our go-forward Business Development plans remain intact. As we have stated in the past, we intend to use our strong Balance Sheet and Financial Flexibility to potentially make an Accretive Acquisition with the aim to broaden our footprint within the Acute Care or Oncology space and solidify our foundation for future growth. We are also currently working with lenders to secure Financing to support a potential Accretive Acquisition. Let me make a few comments on the Pipeline. First, a Global phase II Study is underway for CAL02, a novel First-In-Class agent for the treatment of Severe Community-Acquired Bacterial Pneumonia, used in addition to Standard of Care, including Antibiotic Treatment.

We expect to enroll 276 Patients in 120 Centers in 22 Countries. Second, ENA-001, an investigational one-of-a-kind New Chemical Entity, is an agnostic Respiratory Stimulant being developed by Enalare for the potential treatment of Postoperative Respiratory Depression, Community Drug Overdose, and apnea of prematurity. As a reminder, we acquired approximately 17% Equity Stake in Enalare in exchange for two Upfront Investments paid in August of 2022 and February of 2023, and we have an option to purchase the rest of Enalare in the event specified milestones are achieved. Third, Landiolol NDA is under review at FDA. The filing seeks approval for Landiolol for the short-term reduction of Ventricular Rate in patients with Supraventricular Tachycardia, including Atrial Fibrillation and Atrial Flutter. To recap, as you can see, we had another impressive quarter.

Our plan is to accelerate long-term growth through potential acquisitions and our Pipeline. We believe that we are in a good position to execute on all three aspects of our business, namely strength from our existing product line, potential future Accretive Acquisitions, and the development of our Pipeline. With that, I'll turn the call over to Brian Cahill to discuss our First Quarter Financials. Brian?

Brian Cahill (CFO)

Thank you, Scott, and good morning. In the First Quarter of 2023, Total Revenue was $66.3 million, compared to $115.9 million in the prior year. Net Product Sales during the First Quarter of 2023 were $46.2 million compared to $90.1 million in Q1, 2022, our launch quarter for both PEMFEXY PEMFEXY Net Product Sales were $22.9 million in the First Quarter of compared to $37.2 million in the First Quarter of 2022. we record Revenue on delivery of our product to our direct customers, primarily Wholesalers, which estimates the current and near-term needs of the Wholesaler Channel for our growing product.

As we continue to capture more share of the Pemetrexed Market, customer Inventory Levels may be higher than for similar established product. Vasopressin Net Product Sales were $3.5 million in the First Quarter of 2023. As previously announced, during the First Quarter of 2023, we notified customers and the FDA of our decision to withdraw from the Vasopressin Market. Our Inventory on Hand has been depleted at this time. BELRAPZO Net Product Sales increased to $6.4 million in the First Quarter of 2023, compared to $5.9 million in Q1 of 2022. In First Quarter 2023, RYANODEX Net Product Sales were $8.8 million compared to $6.6 million in Q1 of 2022. Q1 2023 Royalty Revenue was $20.1 million compared to $25.8 million in the prior year quarter.

Royalty Revenues include royalties earned on sales of Bendeka in the U.S. and TREAKISYM in Japan. Gross Margin was 74% in Q1 2023, compared to 76% in the prior year quarter. The decrease was primarily the result of the inclusion of Amortization of Intangible Assets related to the newly acquired products, Barhemsys and Byfavo, which we expect will continue going forward. On the expense front, R&D expenses were $9.3 million for the First Quarter 2023, compared to $6.1 million in Q1 2022. This increase is largely attributable to continuing CMC and Clinical Trial spend on our CAL02 Program and the Barhemsys and Byfavo Pediatric Studies. Excluding Stock-Based Compensation and other non-cash and non-recurring items, First Quarter 2023 non-GAAP R&D Expense was $8.6 million.

SG&A expenses in the First Quarter of 2023 were $28 million compared to $22.2 million in the First Quarter of 2022. This increase was driven by $3.3 million in salary and other personnel-related costs, $2 million in external sales and marketing spend, partially offset by $2 million in lower legal-related costs. Excluding stock-based compensation and other non-cash and non-recurring items, First Quarter 2023 non-GAAP SG&A expense was $23.9 million. Net income for the First Quarter of 2023 was $5.8 million or $0.44 per basic and diluted share, compared to net income of $44.1 million or $3.47 per basic, and $3.41 per diluted share in the prior year quarter.

Adjusted Non-GAAP Net Income for the first quarter of 2023 was $16.5 million, or $1.27 per basic, and Adjusted Non-GAAP Net Income of $52.2 million or $4.10 per basic and $4.04 per diluted share in the prior year quarter. Our adjusted non-GAAP EBITDA was $22.3 million for the First Quarter of 2023. For a full reconciliation of non-GAAP measures to the most comparable GAAP measures, please see the tables at the end of our earnings press release. As of March 31st, 2023, the company had $21.9 million in cash and cash equivalents, $115 million in Net Accounts Receivable, and $77.5 million in outstanding debt.

With that, I'll ask the operator to please open the call for questions. Operator, please go ahead.

Operator (participant)

Thank you. At this time, we will open the floor for questions. If you would like to ask a question, please press the star and one on your touch tone phone. You may remove yourself from the queue at any time by pressing star two. Once again, that is star and one to ask a question. Our first question comes from Tim Lugo with William Blair.

Lachlan Hanbury-Brown (Senior Equity Research Associate)

Hey, guys, this is Lachlan on for Tim. Thanks for taking the question, and congratulations on the strong quarter. On the announcement for securing the Financing for the deal and where you are in that stage, just curious on the rationale for announcing that now rather than, you know, wait until everything is fully signed, sealed and delivered. Brian, on that, just wanted to check if the Guidance you guys provided earlier in the year included any consideration for BD or not.

Brian Cahill (CFO)

All right. Thanks for the, for the question. Let me pick up the why say something now. You know, it's just simple. We're working hard at it. We've been speaking about the potential of an Acquisition for, you know, a number of quarters now. We're just very deliberate in our actions and very selective about what we do. We are moving forward as aggressively as we can to find the right opportunity. This was just a sign that we take the Business Development and the M&A action seriously, and we are lining up lenders, so we're in a position to transact as soon as practical. In terms of the Guidance, Brian, you have anything to add? Sure.

Our Guidance does not contemplate the completion and integration of any M&A, but does have, you know, does have a sliver of investigational work in our G&A, naturally, since we've been doing that for over a year. If that helps.

Lachlan Hanbury-Brown (Senior Equity Research Associate)

Got it. Thanks. Yeah, no, that's helpful. I guess ahead of the Landiolol PDUFA, Scott, just curious about the sort of what we should be expecting for the launch timing. Are you planning to sort of let the Sales Team loose with that immediately, or will you be spending a couple of quarters trying to gain access before they sort of take it out into the field?

Brian Cahill (CFO)

Yeah, that's a, you know, that's a great point. You know, depending on the timing of the approval, we wind up with an approval that could be happening going into the summer months. Probably launching a drug into the summer isn't the most effective way to handle it, especially considering that we're so pleased with the traction we're starting to get with the two Acacia products.

Scott Tarriff (President and CEO)

Again, small base, but this was only the really the first quarter. It's the last two quarters that we've had, the full territories and everybody at full strength. You know, we picked up the 32% growth in the Acacia products. You don't want anything to get in the way launching Landiolol. We're probably better off waiting a little bit, get through a couple more quarters with the Acacia products and not trying to launch something in the middle of the summertime.

Lachlan Hanbury-Brown (Senior Equity Research Associate)

Got it. Thanks, Scott. Appreciate it.

Scott Tarriff (President and CEO)

Welcome.

Operator (participant)

Thank you. Our next question comes from Brandon Folkes with Cantor Fitzgerald.

Brandon Folkes (Managing Director of Biopharma/Biotech Equity Research)

Hi. Thanks for taking my questions. Congratulations on the very strong quarter. Maybe firstly, just on PEMFEXY, can you talk about any sort of benefits in 1Q 2023 that may not endure for the rest of the year, any one-timers? How should we think about the cadence of quarters in 2023? Along those lines, seems like the generic arbitrage is pretty well behind us here. Just is that fair thinking? I'll ask that question then.

Scott Tarriff (President and CEO)

Yeah.

Brandon Folkes (Managing Director of Biopharma/Biotech Equity Research)

Ask some add-ons.

Scott Tarriff (President and CEO)

Brandon, you know, PEMFEXY is really shaping up to be really wonderful for us. Going from the 6% share in Q4 to where we are right now at 15% is really very encouraging. My guess is, you know, as we stated today, based on how we see the trends running, speaking to our customers and just watching this all unfold, that that 15% is going to just continue throughout the year to grow. How high it goes, you know, it's just too difficult to predict right now. With the, you know, the just shy of $23 million we had in Q1, you know, relative to the $67 million that we sold in all of last year, our forecast that we'll sell more than last year's numbers in 2023 is probably looking pretty good.

You know, there's always ins and outs you can't predict in pricing and inventory levels, you know, we would expect what we're seeing now is that $67 million number for the year is looking pretty darn good. We're pretty pleased about the $15 million we spent to buy back that first $85 million of profit. Our expectation is that the share is just gonna continue to grow, and we're in a pretty good place for the year as it relates to PEMFEXY and, you know, couldn't be more pleased with the way the launch is going.

Brandon Folkes (Managing Director of Biopharma/Biotech Equity Research)

Great. Thanks very much. Maybe just changing speed to Barhemsys and Byfavo, can you just provide any feedback you're getting from the field? How should we think about these going forward? Is it just sort of a normal kind of hospital-type launch where it just sort of takes a bit of time or kind of any color you can provide there in terms of how should we think about, maybe the sales rep?

Scott Tarriff (President and CEO)

Well, Brandon, you know, I'm thrilled you asked that question. I would tell you from our standpoint here internally, we're more excited about these two products than we were when we made the acquisition a year ago. The feedback that we're getting has really been tremendous from the users of the product, the nurses and the physicians, and the feedback we're getting from those two groups, by the way the patients feel about the products. You know, as we all know, there's a ramp process that goes through to be able to establish these products in the hospital. I mean, we're extremely pleased with the trajectory so far. You know, 32% growth in a quarter, we expect that market share, that growth to just continue. The feedback has been really just wonderful. We're doing a lot. The J-Code helps.

I think we're just gonna have nice steady ramp out through time. Remember, these products are both protected into the early 30s, so we have plenty of time, and it's going well. We have Dr. Greenberg with us, who's much closer with the physicians and the nurses that we speak to. Mike, maybe you want to say a couple short comments about what you're hearing about the two products.

Mike Greenberg (VP of Medical Affairs)

Sure, Scott. Thank you. I'd just like to reiterate the feedback that you shared, excuse me, on the medical affairs side, we've been hearing exactly the same thing. Regarding Barhemsys, we're starting to see some real-world evidence percolate into meetings and being published. That data echoes what we've seen in our pivotal trials and in fact, in some cases surpasses it. This is a drug that's really seemed to be over-delivering at this point, at least to a certain extent. On the Byfavo side, there's a great increase in accounts that are using Byfavo as well. Again, the feedback has been extraordinary, helping patient throughput. Patients are being sedated for their procedures more rapidly, waking up alert and moving on.

There's a very high level of satisfaction in both the healthcare providers and for the patients. Medical affairs team is really excited about these products and so is the sales team.

Scott Tarriff (President and CEO)

In conclusion, Brandon, I would say that we're just expecting nice, steady growth over the next several years and, you know, many quarters and, you know, it compounds. If you just keep having really nice, solid growth like this quarter-after-quarter-after-quarter-after-quarter, you can see where these two products build in a relatively short period of time. You know what we've been stating as we project where the company is going, you know, fortunately, the products that we sell today are doing rather well, right? Another strong quarter. We've had, you know, several strong quarters of performance now with the products that we sell. 2023 is probably gonna be another very strong year for the company. That gives us time to build the foundation of Barhemsys and Byfavo.

You can just see if this growth continues by the time you get to 2024, 2025 and 2026, how these products can start to be a very significant portion of our earnings and our growth.So far, less than a year into the acquisition, recently having all the territories at full strength, we're pretty excited and pleased and about where we are so far and where we're going.

Brandon Folkes (Managing Director of Biopharma/Biotech Equity Research)

Great. Thanks. One more, if I may, just a clarifying question on the prior question. When you talk about the fact that you're working with lenders for an acquisition, does this imply you have a target that you're ready to move on right now, or are you subject to the financing, or are you just trying to line up the financing so you can move quickly when you do find a suitable target? An asset for me. Thank you.

Scott Tarriff (President and CEO)

There's not much more, Brandon, we can say about that other than the fact that, you know, we've been talking about it for a while, and this is just trying to convey to everybody that we are working diligently and we're very focused. We believe we're in a very unique situation, right? As the industry starts to unfold, if we just take a step back, you know, when we acquired Acacia, there were 70 people in that organization, and we were able to, you know, just run that business with 20, not the full 70 that they had. The way we've built our infrastructure here at Eagle and the way we've prudently managed our cash and our balance sheet, we believe that we can make a very significant acquisition relative to our size and have similar reduction in cost.

We can probably take in another large product, you know, probably more in the oncology space than the hospital space right now, and probably bring in a really tremendous amount of synergy when we bring, you know, if we bring a company into the organization. It's a unique situation that we find ourselves in, one, having the infrastructure to be able to take advantage of the synergy, and two, having the financial wherewithal to make a rather large accretive situation. Based on the historical positive situation we found ourselves in right now, having those factors come together, you know, we have to be aggressive. We need to take advantage of it. It's a, it's an opportunity we can't pass for our shareholders. We're very focused. We'll just have to see how things unfold over time here.

The message is, we do take this seriously, and we are trying our best to be able to bring a company into Eagle and take advantage of all of this.

Brandon Folkes (Managing Director of Biopharma/Biotech Equity Research)

Great. Thank you very much.

Operator (participant)

Thank you. Once again, if you would like to ask a question, please press star 1 at this time. Our next question will come from David Amsellem with Piper Sandler.

David Amsellem (Managing Director and Senior Research Analyst)

Thanks. Just a couple. Can you size up the opportunity for landiolol and more interested in particular how you think about the initial ramp here? That's number one. Number two is, I know there's a lot you can't say about the acquisition, or what you're contemplating, but I guess the question here is just thinking more broadly. Are you still very much wedded to the hospital space, given just the financial pressures that we're seeing in the space? Do you want to think more expansively about the business, or is this mainly just hospital-focused? Thank you.

Scott Tarriff (President and CEO)

David, thank you for all of that. Let's take the second question first and talk a little bit more about the acquisition. You know, we just spent a lot of time speaking about the Barhemsys and Byfavo situation, and it does, it takes a lot of effort, and we're very pleased with the ramp. We have the hospital business that I would call more saturated right now because we do have the two products that we're in launch mode for. Then as you bring up in your first question, we have the landiolol situation coming up once it's approved. So I would say it's probably more likely that an acquisition that we make in the short term would fall more in the Oncology Space than it would in the hospital space.

Mostly, you know, the Oncology business right now is a, just a wonderful place to be in the country. We think we can help a number of patients and at the same time help our shareholders. It's the Oncology side of our business where we have so much room from an Infrastructure standpoint. I think if I can try to explain this, you know, the clearest way I can, you know, we can probably bring a significant Oncology product into our company right now without needing a heck of a lot of additional expense. You know, I don't mean direct marketing from that standpoint, but, you know, the Infrastructure that we have could probably support a large Oncology product with a minimal amount of additional spending. That's the situation we need to take advantage of.

If we're able to do what we're hoping to do, it's likely, it's more likely to be on the Oncology side than the hospital side right now. That goes into your Landiolol question, right? We'll launch it. It'll ramp. That's the way these products work. It'll be the same type of ramp that you normally see in the hospital space. It'll just fortify what we have. We'll see how that goes. But we are very concentrated right now in Oncology.

David Amsellem (Managing Director and Senior Research Analyst)

Okay, that's helpful. Thank you.

Scott Tarriff (President and CEO)

Thank you.

Operator (participant)

Thank you. We have no further questions in queue at this time. I will now turn the call back over to Scott Tarriff for any additional or closing remarks.

Scott Tarriff (President and CEO)

Well, thank you everyone for joining the call today. You know, clearly, obviously, we believe we're poised for another solid year in 2023. We look forward to updating you as we advance our business plans. You know, we think we have really very strong vision of the future. Let's see how it unfolds. As always, we appreciate your ongoing support for Eagle. Thank you, everybody, and stay well.

Operator (participant)

This concludes today's call. Thank you for your participation. You may disconnect at any time.